BML, Inc. logo

BML, Inc.

4694.T

JPXHealthcareMedical - Diagnostics & Research

Latest quote

¥3,635

+¥10.00 · +0.28%

Aug 24, 3:30 PM JST

4694.T company overview

Regular session · JST · Market data may be delayed.

Company profile

Company website

BML, Inc. is a Japanese corporation specializing in a comprehensive range of laboratory diagnostics and related services. The company conducts standard analyses such as biochemical and hematological screenings, in addition to advanced specialized tests including radioimmunoassay (RIA), cellular diagnostics, immunology, and DNA analysis. It also provides microbiological assessments for medical and pharmaceutical organizations, along with diagnostic services covering critical areas like oncology, infectious diseases, metabolic disorders (diabetes, hypertension), allergies, and genetic studies. To optimize laboratory operations, BML develops proprietary automation systems, Frontier and Symphony, designed to streamline processes from initial sample sorting and dispensing through to subsequent testing. The firm also supports medical information networking via electronic health records and offers preventative healthcare solutions. BML's extensive service portfolio includes food safety and environmental health. Its food division provides comprehensive hygiene control and processing support, encompassing contractual microbiological testing for raw ingredients, prepared, and processed foods. This extends to environmental hygiene assessments for food facilities and kitchens, general microorganism testing, and the evaluation of genetically modified organisms. Environmental services comprise drinking water and wastewater analysis, occupational health management (measuring airborne substances like ethylene oxide, formaldehyde, organic solvents, and dust), comprehensive indoor environmental monitoring (identifying contaminants and other variables), and biological dioxin surveillance. Moreover, BML performs analyses for residual agricultural chemicals, offers dental diagnostics for caries and periodontal diseases, provides consulting for pharmaceutical product approvals, conducts investigative analyses for drug manufacturers, and performs gene expression analysis, specifically identifying genes linked to infectious disease susceptibility. Founded in 1955, BML, Inc. is headquartered in Tokyo, Japan.

Industry
Medical - Diagnostics & Research
Sector
Healthcare
Headquarters
JP
CEO
Kensuke Kondo
Listed since
Apr 25, 2001
Employees
4,612

Market position

Volume
53.2K
0.67× average
Average volume
79.45K
Average daily volume
Market cap
136.25B JPY
Beta
0.24
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
17.4×
P/B (TTM)
1.07×
P/S (TTM)
0.9×
Dividend yield
3.44%

Profitability & efficiency

Gross margin
32.57%
Operating margin
7.02%
Net margin
5.20%

Financial health

Debt / equity
0.04×
Altman Z-score
4.03
Piotroski F-score
5 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends51%34%17%0%Gross margin, FY2021: 46.73%Gross margin, FY2022: 38.53%Gross margin, FY2023: 33.07%Gross margin, FY2024: 32.03%Gross margin, FY2025: 32.40%Operating margin, FY2021: 26.28%Operating margin, FY2022: 15.01%Operating margin, FY2023: 6.65%Operating margin, FY2024: 6.54%Operating margin, FY2025: 6.94%Net margin, FY2021: 18.13%Net margin, FY2022: 9.77%Net margin, FY2023: 4.37%Net margin, FY2024: 4.37%Net margin, FY2025: 5.16%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 46.73%. Gross margin FY2022 38.53%. Gross margin FY2023 33.07%. Gross margin FY2024 32.03%. Gross margin FY2025 32.40%. Operating margin FY2021 26.28%. Operating margin FY2022 15.01%. Operating margin FY2023 6.65%. Operating margin FY2024 6.54%. Operating margin FY2025 6.94%. Net margin FY2021 18.13%. Net margin FY2022 9.77%. Net margin FY2023 4.37%. Net margin FY2024 4.37%. Net margin FY2025 5.16%.

Income trends

Revenue

150.26B JPY+4.94%

Operating income

10.42B JPY+11.30%

Net income

7.75B JPY+23.69%
Income trends across reported periods204.07B JPY132.06B JPY60.04B JPY−11.97B JPYRevenue, FY2021: 186.07B JPYRevenue, FY2022: 159.46B JPYRevenue, FY2023: 137.96B JPYRevenue, FY2024: 143.19B JPYRevenue, FY2025: 150.26B JPYOperating income, FY2021: 48.89B JPYOperating income, FY2022: 23.94B JPYOperating income, FY2023: 9.17B JPYOperating income, FY2024: 9.37B JPYOperating income, FY2025: 10.42B JPYNet income, FY2021: 33.74B JPYNet income, FY2022: 15.58B JPYNet income, FY2023: 6.04B JPYNet income, FY2024: 6.26B JPYNet income, FY2025: 7.75B JPYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 186.07B JPY. Revenue FY2022 159.46B JPY. Revenue FY2023 137.96B JPY. Revenue FY2024 143.19B JPY. Revenue FY2025 150.26B JPY. Operating income FY2021 48.89B JPY. Operating income FY2022 23.94B JPY. Operating income FY2023 9.17B JPY. Operating income FY2024 9.37B JPY. Operating income FY2025 10.42B JPY. Net income FY2021 33.74B JPY. Net income FY2022 15.58B JPY. Net income FY2023 6.04B JPY. Net income FY2024 6.26B JPY. Net income FY2025 7.75B JPY.
Metric (JPY)FY2025FY2024FY2023FY2022FY2021
Revenue150.26B JPY143.19B JPY137.96B JPY159.46B JPY186.07B JPY
Cost of goods sold101.57B JPY97.33B JPY92.34B JPY98.02B JPY99.12B JPY
Gross profit48.69B JPY45.86B JPY45.63B JPY61.45B JPY86.95B JPY
Research and development260M JPY275M JPY271M JPY302M JPY
Selling, general, and administrative38.27B JPY36.24B JPY36.19B JPY37.24B JPY37.76B JPY
Operating expenses38.27B JPY36.5B JPY36.46B JPY37.51B JPY38.06B JPY
Interest income106M JPY
Interest expense119M JPY118M JPY104M JPY40M JPY36M JPY
Depreciation and amortization9.12B JPY7.72B JPY6.79B JPY6.35B JPY5.89B JPY
Operating income10.42B JPY9.37B JPY9.17B JPY23.94B JPY48.89B JPY
Net income7.75B JPY6.26B JPY6.04B JPY15.58B JPY33.74B JPY

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
0%
0 beats, 1 miss, 0 met estimates
Average EPS surprise
-15.64%
1 comparable report
Latest EPS result
52.85

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates6550.9336.8722.8Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Q4 2024, reported Nov 8, 2024: actual 44.08, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Feb 7, 2025: actual 47.02, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 9, 2025: actual 25.71, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 8, 2025: actual 47.75, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 7, 2025: actual 61.63, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 6, 2026: actual 62.09, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 13, 2026: actual 32.07, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 7, 2026: actual 52.85, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates40.66B37.85B35.05B32.24BQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 7, 2025: actual 37.21B JPY, estimate 36.02B JPY, surprise +3.29%, Beat. Q2 2025, reported May 9, 2025: actual 34.61B JPY, estimate 33.8B JPY, surprise +2.40%, Beat. Q3 2025, reported Aug 8, 2025: actual 38.03B JPY, estimate 35.7B JPY, surprise +6.52%, Beat. Q4 2025, reported Nov 7, 2025: actual 37.6B JPY, estimate 38B JPY, surprise -1.05%, Miss. Q1 2026, reported Feb 6, 2026: actual 38.85B JPY, estimate 37.2B JPY, surprise +4.43%, Beat. Q2 2026, reported May 13, 2026: actual 35.79B JPY, estimate 36.53B JPY, surprise -2.02%, Miss. Q3 2026, reported Aug 7, 2026: actual 39.04B JPY, estimate 39.1B JPY, surprise -0.16%, Miss. Q4 2026, reported Nov 6, 2026: actual —, estimate 38.9B JPY, surprise —, Comparison unavailable.

Corporate actions

Corporate action history

Stock split

Effective Aug 29, 2016

2:1

4694.T peers

ETFs holding 4694.T

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research 4694.T

research.disclaimer